QbD-driven development and validation of an efficient bioanalytical UPLC method for estimation of olmesartan medoxomil

References

• Wren, S. A.; Tchelitcheff, P. Use of Ultra-performance Liquid Chromatography in Pharmaceutical Development. J. Chromatogr. A 2006, 1119(1–2), 140–146.
   PubMed Web of Science ®Google Scholar
• Tiwari, G.; Tiwari, R. Bioanalytical Method Validation: An Updated Review. Pharm. Methods 2011, 1(1), 25–38.
   Google Scholar
• Wal, P.; Kumar, B.; Bhandari, A.; Rai, A. K.; Wal, A. Bioanalytical Method Development—Determination of Drugs in Biological Fluids. J. Pharm. Sci. Technol. 2010, 2(10), 333–347.
   Google Scholar
• Shah, V. P.; Midha, K. K.; Dighe, S.; McGilveray, I. J.; Skelly, J. P.; Yacobi, A.; Layloff, T.; Viswanathan, C. T.; Cook, C. E.; McDowall, R. D. et al. Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies. Conference Report. Eur. J. Drug Metab. Pharmacokinet. 1991, 16(4), 249–255.
   PubMed Web of Science ®Google Scholar
• Laeis, P.; Puchler, K.; Kirch, W. The Pharmacokinetic and Metabolic Profile of Olmesartan Medoxomil Limits the Risk of Clinically Relevant Drug Interaction. J. Hypertens. Suppl. 2001, 19(1), S21–S32.
   PubMedGoogle Scholar
• Raghunathan, K.; Reddy, J. M.; Manasa, R. Stability Indicating RP-HPLC Method Development and Validation of Olmesartan Medoxomil. Asian J. Pharm. Biol. Res. 2011, 1(2), 79–86.
   Google Scholar
• Hamrapurkar, P. D.; Gadapayale, K. K. Optimization and Validation of Rp-HPLC Stability Indicating Method for Determination of Olmesartan Medoxomil and its Degraded Product. Int. J. Appl. Sci. Eng. 2013, 11(2), 137–147.
   Google Scholar
• Tambe, S. R.; Shinde, R. H.; Gupta, L. R.; Pareek, V.; Bhalerao, S. B. Development of LLE and SPE procedures and its applications for determination of olmesartan In human plasma using RP-HPLC and HPTLC. J. Liq. Chromatogr. Relat. Technol. 2012, 35, 423–430.
   Google Scholar
• Gandurib, R. B.; Lankaa, R. A.; Pamidia, S.; Peddareddigarib, J. R.; Mohammed, M. New RP-HPLC Method for the Determination of Olmesartan Medoxomil in Tablet Dosage Form. Eurasian J. Anal. Chemistry. 2010, 5(2), 145–151.
   Google Scholar
• Sharma, R. N.; Pancholi, S. S. RP-HPLC-DAD Method for Determination of Olmesartan Medoxomil in Bulk and Tablets Exposed to Forced Conditions. Acta Chromatographia 2010, 60(1), 13–24.
   Google Scholar
• Pai, N. R.; Sawant, S. S. Development and Validation of New RP-HPLC Method for Determining Impurity Profiling in Olmesartan Medoxomil Drug as Well as in Tablet Dosage Form. Der Pharma Chemica. 2013, 5(4), 274–281.
   Google Scholar
• Raja, S.; Kumari, K. S.; Rao, A. N.; Reddy, I. U.; Raju, M. N. Development of a Stability-indicating UPLC Method for Determination of Olmesartan Medoxomil and its Degradation Products in Active Pharmaceutical Ingredient and Dosage Forms. J. Liq. Chromatogr. Relat. Technol. 2012, 35(8), 1011–1026.
   Web of Science ®Google Scholar
• Vaidya, V. V.; Roy, S. M. N.; Yetal, S. M.; Joshi, S. S.; Parekh, S. A. LC–MS–MS Determination of Olmesartan in Human Plasma. Chromatographia 2007, 67(1–2), 147–150.
   Web of Science ®Google Scholar
• Liu, D.; Hu, P.; Matsushima, N.; Li, X.; Li, L.; Jiang, J. Quantitative Determination of Olmesartan in Human Plasma and Urine by Liquid Chromatography Coupled to Tandem Mass Spectrometry. J. Chromatogr. B 2007, 856(1–2), 190–197.
   PubMed Web of Science ®Google Scholar
• Monks, K.; Molnar, I.; Rieger, H. J.; Bogati, B.; Szabo, E. Quality by Design: Multidimensional Exploration of the Design Space in High Performance Liquid Chromatography Method Development for Better Robustness Before Validation. J. Chromatogr. A 2011, 1232, 218–230.
   PubMed Web of Science ®Google Scholar
• Garg, L. K.; Reddy, V. S.; Sait, S. S.; Krishnamurthy, T.; Vali, S. J.; Reddy, A. M. Quality by Design: Design of Experiments Approach Prior to the Validation of a Stability-indicating HPLC Method for Montelukast. Chromatographia 2013, 76, 1697–1706.
   Web of Science ®Google Scholar
• Awotwe-Otoo, D.; Agarabi, C.; Faustino, P. J.; Habib, M. J.; Lee, S.; Khan, M. A.; Shah, R. B. Application of Quality by Design Elements for the Development and Optimization of an Analytical Method for Protamine Sulfate. J. Pharm. Biomed. Anal. 2012, 62, 61–67.
   PubMed Web of Science ®Google Scholar
• Skrdla, P. J.; Wang, T.; Antonucci, V.; Dowling, T.; Ge, Z.; Ellison, D.; Curran, J.; Mohan, G.; Wyvratt, J. Use of a Quality-by-design Approach to Justify Removal of the HPLC Weight % Assay From Routine API Stability Testing Protocols. J. Pharm. Biomed. Anal. 2009, 50(5), 794–796.
   PubMed Web of Science ®Google Scholar
• Murthy, M. V.; Krishnaiah, C.; Srinivas, K.; Rao, K. S.; Kumar, N. R.; Mukkanti, K. Development and Validation of RP-UPLC Method for the Determination of Darifenacin Hydrobromide, its Related Compounds and its Degradation Products Using Design of Experiments. J. Pharm. Biomed. Anal. 2012, 72, 40–50.
   PubMed Web of Science ®Google Scholar
• Schmidt, A. H.; Molnár, I. Using an Innovative Quality-by-design Approach for Development of a Stability Indicating UHPLC Method for Ebastine in the API and Pharmaceutical Formulations. J. Pharm. Biomed. Anal. 2013, 78–79, 65–74.
   PubMed Web of Science ®Google Scholar
• Beg, S.; Kohli, K.; Swain, S.; Hasnain, M. S. Development and Validation of RP-HPLC Method for Quantitation of Amoxicillin Trihydrate in Bulk and Pharmaceutical Formulations Using Box–Behnken Experimental Design. J. Liq. Chromatogr. Relat. Technol. 2011, 35, 393–406.
   Web of Science ®Google Scholar
• Imam, S. S.; Aqil, M.; Akhtar, M.; Sultana, Y.; Ali, A. Optimization of Mobile Phase by 32-mixture Design for the Validation and Quantification of Risperidone in Bulk and Pharmaceutical Formulations Using RP-HPLC. Anal. Methods 2013, 6, 222–228.
   Web of Science ®Google Scholar
• Kurmi, M.; Kumar, S.; Singh, B.; Singh, S. Implementation of Design of Experiments for Optimization of Forced Degradation Conditions and Development of a Stability-indicating Method for Furosemide. J. Pharm. Biomed. Anal. 2014, 96C, 135–143.
   Web of Science ®Google Scholar
• Khurana, R. K.; Beg, S.; Lal, D.; Katare, O. P.; Singh, B. Analytical Quality by Design Approach for Development of a Validated Bioanalytical UPLC Method of Docetaxel Trihydrate. Curr. Pharm. Anal. 2015, 11(3), 180–192.
   Web of Science ®Google Scholar
• Beg, S.; Chaudhary, V.; Sharma, G.; Garg, B.; Panda, S. S.; Singh, B. QbD-Oriented Development and Validation of a Bioanalytical Method for Nevirapine with Enhanced Liquid-liquid Extraction and Chromatographic Separation. Biomed. Chromatogr. 2016, 30(6), 818–828.
   PubMed Web of Science ®Google Scholar
• Singh, B.; Kumar, R.; Ahuja, N. Optimizing Drug Delivery Systems Using Systematic “Design of Experiments.” Part I: Fundamental Aspects. Crit. Rev. Ther. Drug Carrier Syst. 2005, 22(1), 27–105.
   PubMed Web of Science ®Google Scholar
• Singh, B.; Raza, K.; Beg, S. Developing “Optimized” Drug Products Employing “Designed” Experiments. Chem. Industry Digest. 2013, 6, 70–76.
   Google Scholar
• Guideline of International Conference on Harmonization, Validation of Analytical Procedures: Text and Methodology. 2005.
   Google Scholar
• Tambe, S. R.; Shinde, R. H.; Gupta, L. R.; Pareek, V.; Bhalerao, S. B. Development of LLE and SPE Procedures and its Applications for Determination of Olmesartan in Human Plasma Using RP-HPLC and HPTLC. J. Liq. Chromatogr. Relat. Technol. 2012, 35, 423–430.
   Google Scholar
• Hamrapurkar, P. D.; Gadapayale, K. K. Optimization and Validation of RP-HPLC Stability Indicating Method for Determination of Olmesartan Medoxomil and its Degraded Product. Int. J. Appl. Sci. Eng. 2013, 11(2), 137–147.
   Google Scholar